Guttify in Talks to Raise INR 20 Cr for RNA-Based Gut Health Innovation
According to sources, 60% of the round is expected to be closed with a well-known VC firm specializing in healthcare and consumer investments.
Guttify, a gut health startup by Lifechart, is in advanced talks with leading venture capital firms to raise INR 20 crore in an upcoming funding round.
According to sources, 60% of the round is expected to be closed with a well-known VC firm specializing in healthcare and consumer investments.
The company focuses on a “Diagnosis-First” model for addressing gut health concerns and has been gaining traction in the wellness and consumer healthcare space.
Backed by UNICHEM Laboratories’ family office and existing investors, Guttify recently secured $360,000 in extended seed funding in May 2025, bringing its total funding to over $1 million.
The startup has also appointed Prashant Pitti, Founder of EaseMyTrip and Optimio, as a strategic advisor and investor.
“Our mission has always been to help people solve chronic gut health issues from the core using the power of science and diagnostics. The new funding will be used to scale product development, expand distribution, and further invest in research to enhance personalized gut care solutions,” said Mukul Shah, co-founder at Guttify.
As part of its upcoming innovation cycle, the startup is preparing to launch RNA gene-based DIY gut testing kits. Claimed to be the first in India, these kits are designed to deliver results within 24 hours. The solution aims to enable accessible, non-invasive gut health testing at home without requiring clinical visits.
